ValiRx PLC Exercise of Warrant (2523Y)
September 07 2020 - 8:30AM
UK Regulatory
TIDMVAL
RNS Number : 2523Y
ValiRx PLC
07 September 2020
VALIRX PLC
("ValiRx", the "Company" or the "Group")
Exercise of Warrant
London, UK 7 September 2020: ValiRx Plc (AIM: VAL), the clinical
stage biotechnology company announces it has received notification
for the exercise of a warrant over 215,384 ordinary shares in the
Company at an exercise price of 16.25 pence per share providing the
Company with proceeds of GBP35,000 ("Warrant Exercise").
Application will be made to the London Stock Exchange to admit
the 215,384 new ordinary shares resulting from the Warrant Exercise
to trading on AIM. Admission of the new ordinary shares is expected
to occur on or around 11 September 2020. The new ordinary shares
will rank pari passu with the existing ordinary shares.
For the purposes of the Disclosure and Transparency Rules,
following the issue of shares detailed above as a result of the
Warrant Exercise, the enlarged issued share capital of the Company
will comprise 57,319,423 ordinary shares of 0.1 pence each. The
Company does not hold any shares in treasury. The above figure may
be used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company, under
the Disclosure and Transparency Rules.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information please contact:
ValiRx plc Tel: +44 (0) 20 7073
2628
www.valirx.com
Suzanne Dilly Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213
Adviser) 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Peterhouse Capital Limited (Sole Broker) Tel: +44 (0) 20 7469
Duncan Vasey / Lucy Williams / Eran Zucker 0930
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOELRMTTMTMMBFM
(END) Dow Jones Newswires
September 07, 2020 08:30 ET (12:30 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2023 to Apr 2024